Otonomy Reports Second Quarter 2020 Financial Results and Provides Corporate Update
04 août 2020 16h22 HE
|
Otonomy, Inc.
Positive top-line results reported for Phase 1/2 trial of OTO-313 in tinnitus patientsPublic offering completed for total gross proceeds of $69.1 millionResults from Phase 3 trial of OTIVIDEX® in...
Otonomy Announces Exclusive License Agreement with Kyorin for Novel Compound in OTO-6XX Hearing Loss Program
03 août 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced an...
Otonomy to Report Second Quarter 2020 Financial Results and Provide Corporate Update
28 juil. 2020 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
13 juil. 2020 16h01 HE
|
Otonomy, Inc.
SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy Announces Pricing of $60.1 Million Public Offering
09 juil. 2020 09h00 HE
|
Otonomy, Inc.
SAN DIEGO, July 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy Announces Proposed Public Offering
08 juil. 2020 16h03 HE
|
Otonomy, Inc.
SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Provides Update on OTIVIDEX® Program
06 juil. 2020 16h02 HE
|
Otonomy, Inc.
SAN DIEGO, July 06, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided an...
Otonomy Provides Update on Clinical Trials and Development Programs
15 juin 2020 16h05 HE
|
Otonomy, Inc.
Results from Phase 3 trial of OTIVIDEX® in Ménière’s disease expected in first quarter of 2021Results from Phase 1/2 trial of OTO-313 in tinnitus expected in July 2020Results from Phase 1/2 trial of...
Otonomy to Present at Raymond James 2020 Human Health Innovation Conference
11 juin 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy to Hold Virtual Annual Meeting of Stockholders for 2020
10 juin 2020 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, June 10, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...